PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-304.05%
Negative net income growth while CRVO stands at 187.19%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.69%
Well above CRVO's 136.11% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
176.34%
Lower AP growth vs. CRVO's 7041.80%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-34.25%
Both reduce yoy usage, with CRVO at -213.61%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
198.30%
Some yoy increase while CRVO is negative at -929.12%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
56.08%
Some CFO growth while CRVO is negative at -77.94%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
100.00%
We expand invests by 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
42.27%
We repay more while CRVO is negative at -100.00%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.